| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
IAV-IN-5 (compound 3h) (25-100 μM; 24 hours post-infection) dose-dependently inhibited RIG-I protein expression and phosphorylated NF-κB levels in A549 cells infected with A/Weiss/43 (H1N1), blocking the activation of the NF-κB inflammatory signaling pathway [1].
|
|---|---|
| ln Vivo |
IAV-IN-5 (compound 3h) (25-100 mg/kg/d; gavage; once daily for 6 days) reduced pathological damage caused by influenza A virus in BALB/c mice in a dose-dependent manner. The 100 mg/kg/d dose reduced the lung index by 50.26%, decreased viral load, inhibited the expression of inflammatory cytokines, and reduced alveolar cell apoptosis [1]. IAV-IN-5 (100 mg/kg/d; gavage; once daily for 6 days) showed good in vivo safety in healthy BALB/c mice, and no organ toxicity or changes in blood/serum biochemical parameters were observed [1].
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: A549 cells infected with A/Weiss/43 (H1N1) virus Tested Concentrations: 25, 50, 100 μM Incubation Duration: 24 hours post-infection Experimental Results: RIG-I protein expression was dose-dependently inhibited compared with the virus control group. pNF-κB levels were significantly reduced compared with the virus control group. |
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 5 weeks old, 13-17 g, intranasally inoculated with A/Weiss/43 H1N1 virus) [1]
Doses: 25 mg/kg/d; 50 mg/kg/d; 100 mg/kg/d Route of Administration: Gavage; once daily for 6 consecutive days Experimental Results: Reduced virus-induced weight loss and improved mouse survival. Reduced hemorrhagic lesions and edema; the 100 mg/kg/d dose caused only mild edema, similar to oseltamivir. Lung index was inhibited by 23.76% (25 mg/kg/d), 38.24% (50 mg/kg/d) and 50.26% (100 mg/kg/d), respectively. The high dose showed better inhibitory effects than oseltamivir. It can reduce alveolar wall thickening, interstitial edema, and inflammatory infiltration; the 100 mg/kg/d dose is comparable to oseltamivir in maintaining alveolar structural integrity. Influenza virus NP protein staining in lung tissue showed a dose-dependent decrease, with the weakest signal in the 100 mg/kg/d dose group. On days 2, 4, and 6 post-infection, the mRNA levels of viral NP and M2 genes in lung tissue decreased in all dose groups. On day 6 post-infection, the mRNA expression of inflammatory factors (RIG-I, TLR3, IRF3, ASC, iNOS, IL-4, IL-6, IFN-α) in lung tissue was downregulated in all dose groups. Apoptotic cells in lung tissue decreased in a dose-dependent manner; the 100 mg/kg/d dose group was comparable to oseltamivir. Animal/Disease Models:BALB/c (female, 5 weeks old, 13-17 g) [1] Doses: 100 mg/kg/day Route of Administration: Gavage; once daily for 6 consecutive days Experimental Results: No obvious pathological changes, tissue damage, cell degeneration/necrosis or inflammatory cell infiltration were observed. Routine blood indicators remained within the normal physiological range. Serum biochemical indicators were close to the normal control level. |
| References |
| Molecular Formula |
C22H23NO3S
|
|---|---|
| Molecular Weight |
381.49
|
| CAS # |
3038861-11-6
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=S(C1=CC=C(C)C=C1)(N(C2=C(C)[C@@]3([H])CCCC([C@@]23[H])=O)C4=CC=CC=C4)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6213 mL | 13.1065 mL | 26.2130 mL | |
| 5 mM | 0.5243 mL | 2.6213 mL | 5.2426 mL | |
| 10 mM | 0.2621 mL | 1.3107 mL | 2.6213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
